F
Francesco Agustoni
Researcher at University of Milan
Publications - 43
Citations - 819
Francesco Agustoni is an academic researcher from University of Milan. The author has contributed to research in topics: Medicine & Lung cancer. The author has an hindex of 9, co-authored 26 publications receiving 548 citations.
Papers
More filters
Journal ArticleDOI
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study.
Marina Chiara Garassino,Jennifer G. Whisenant,Li-Ching Huang,Annalisa Trama,Valter Torri,Francesco Agustoni,Javier Baena,Giuseppe Luigi Banna,Rossana Berardi,Anna Cecilia Bettini,Emilio Bria,Matteo Brighenti,Jacques Cadranel,Alessandro De Toma,Claudio Chini,Alessio Cortellini,Enriqueta Felip,Giovanna Finocchiaro,Pilar Garrido,Carlo Genova,Raffaele Giusti,Vanesa Gregorc,Francesco Grossi,Federica Grosso,Salvatore Intagliata,Nicla La Verde,Stephen V. Liu,Julien Mazieres,Edoardo Mercadante,Olivier Michielin,Gabriele Minuti,Denis Moro-Sibilot,Giulia Pasello,Antonio Passaro,Vieri Scotti,Piergiorgio Solli,Elisa Stroppa,Marcello Tiseo,Giuseppe Viscardi,Luca Voltolini,Yi-Long Wu,Silvia Zai,Vera Pancaldi,Anne Marie C. Dingemans,Jan P. van Meerbeeck,Fabrice Barlesi,Heather A. Wakelee,Solange Peters,Leora Horn +48 more
TL;DR: With an ongoing global pandemic of COVID-19, the data suggest high mortality and low admission to intensive care in patients with thoracic cancer and whether mortality could be reduced with treatment in intensive care remains to be determined.
Journal ArticleDOI
Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations
E.R. Haspinger,Francesco Agustoni,Valter Torri,Francesco Gelsomino,Marco Platania,Nicoletta Zilembo,Rosaria Gallucci,Marina Chiara Garassino,Michela Cinquini +8 more
TL;DR: Three EGFR tyrosine kinase inhibitors have been compared to standard chemotherapy as up-front treatment in patients with advanced EGFR-positive NSCLC and showed that all treatments had similar efficacy but they differ for toxicities.
Journal ArticleDOI
A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin.
Paolo Bossi,Diego Cortinovis,S. Fatigoni,M. Cossu Rocca,Alessandra Fabi,P. Seminara,Carla B. Ripamonti,Salvatore Alfieri,Roberta Granata,Cristiana Bergamini,Francesco Agustoni,P. Bidoli,Franco Nolè,M.A. Pessi,Fabio Macchi,L. Michellini,F. Montanaro,Fausto Roila +17 more
TL;DR: In patients treated with high-dose cisplatin, the daily addition of ginger, even if safe, did not result in a protective effect on CINV, and the favorable effect observed on nausea in subgroups at particular risk of nausea (females; HNC) deserves specific investigation.
Journal ArticleDOI
Emerging toxicities in the treatment of non-small cell lung cancer: Ocular disorders
Francesco Agustoni,Marco Platania,Milena Vitali,Nicoletta Zilembo,E.R. Haspinger,Valentina Sinno,Rosaria Gallucci,Filippo de Braud,Marina Chiara Garassino +8 more
TL;DR: The principal clinical presentations of ocular toxicity arising from chemotherapy, target therapies, and newly developed drugs are reviewed and some recommendations for monitoring and management of ophthalmic complications are provided.
Journal ArticleDOI
Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors
Danila Serpico,Annalisa Trama,E.R. Haspinger,Francesco Agustoni,Laura Botta,Rossana Berardi,Giovannella Palmieri,Paolo Andrea Zucali,Rosaria Gallucci,Massimo Broggini,Gemma Gatta,U. Pastorino,Giuseppe Pelosi,F. de Braud,Marina Chiara Garassino +14 more
TL;DR: Data indicate that anti-IGF1R monoclonal antibodies, and inhibitors of angiogenesis, somatostatin receptors, histone deacetylase, mammalian target of rapamycin, and cyclin-dependent kinases may be active against TETs.